Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sierra Oncology Reports Second Quarter Results

SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized...

SRRA : 1.98 (unch)
Sierra Oncology Reports Second Quarter Results

- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized...

SRRA : 1.98 (unch)
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

- Presentation scheduled for 9:10 a.m. ET on August 15, 2018 -

SRRA : 1.98 (unch)
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

- Presentation scheduled for 9:10 a.m. ET on August 15, 2018 -

SRRA : 1.98 (unch)
ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

SRRA : 1.98 (unch)
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 5.28 (+4.55%)
ONCE : 61.59 (+2.43%)
SRRA : 1.98 (unch)
Bladder Cancer: Pipeline Review, H1 2018 - Key Company Analysis, Drug Profiles, and Opportunities - ResearchAndMarkets.com

The "Bladder Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information...

BAYRY : 21.9450 (-4.02%)
JNJ : 132.58 (+1.65%)
MRK : 68.92 (+2.30%)
SRRA : 1.98 (unch)
ALPMF : 16.3600 (-2.33%)
NVS : 82.20 (+0.45%)
ADAP : 8.81 (+2.20%)
AMGN : 196.71 (+0.74%)
CELGZ : 1.49 (+2.05%)
PFE : 41.42 (+0.63%)
BMY : 61.13 (+1.44%)
FSCGF : 5.3000 (unch)
AZN : 37.96 (-1.27%)
AAVXF : 6.9300 (-5.71%)
LLY : 104.63 (+1.26%)
SGEN : 74.34 (+0.60%)
ESALF : 85.0000 (-2.86%)
GSK : 40.88 (+1.04%)
BVNKF : 29.2500 (+1.92%)
MKKGY : 20.5200 (+0.39%)
OPHLF : 23.1500 (-10.65%)
Can The Uptrend Continue for Sierra Oncology (SRRA)?

Investors certainly have to be happy with Sierra Oncology, Inc. (SRRA) and its short term performance

SRRA : 1.98 (unch)
Sierra Oncology to Present at the Jefferies Global Healthcare Conference in New York

Presentation scheduled for 8:30 a.m. ET on June 7, 2018 -

SRRA : 1.98 (unch)
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 5.28 (+4.55%)
ONCE : 61.59 (+2.43%)
SRRA : 1.98 (unch)
Sierra Oncology Reports First Quarter Results

- SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1 -driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - ...

SRRA : 1.98 (unch)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 1.98 (unch)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

- Two posters reporting activity for SRA737 with PARPi (in CCNE1 -driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this combination...

SRRA : 1.98 (unch)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

SRRA : 1.98 (unch)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

- Presentation scheduled for 3:00 p.m. ET on March 23, 2018 -

SRRA : 1.98 (unch)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

SRRA : 1.98 (unch)
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RIOT, SAGE, SRPT, and SRRA which can be accessed for free by signing up to www.wallstequities.com/registration....

SRPT : 128.78 (+2.43%)
SRRA : 1.98 (unch)
RIOT : 5.45 (+1.87%)
SAGE : 148.80 (+1.19%)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

SRRA : 1.98 (unch)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

VANCOUVER , March 14, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics...

SRRA : 1.98 (unch)
Sierra Oncology Announces Pricing of Public Offering of Common Stock

VANCOUVER , March 2, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage...

SRRA : 1.98 (unch)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC +0.10 , FTNT +0.30 , CAKE -0.05 , PLT +0.03 , AEO +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are trading 4 to 5 cents higher in the front months on Thursday. Help is coming from decent export sales data and spill over from soybean and wheat. The weekly FAS Export Sales report indicated old crop sales on the light side of trade e...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar